A review of emerging trends in the treatment of tuberculosis
Source abstract
Abstract
This review attempts to summarize the information available on emerging trends in the treatment of tuberculosis caused by the bacteria Mycobacterium tuberculosis. Nanostructured biomaterials, liposomes, microparticles and solid lipid nanoparticles have unique physicochemical properties such as particularly small and convenient size, sustained release, great surface area to mass ratio and high reactivity with structure. These properties can be useful in easing the administration of antimicrobial drugs, thereby reducing the number of limitations in long-established antimicrobial therapeutics. In recent years, the encapsulation of antimicrobial drugs in all carrier systems has emerged as an innovative and promising change that increases therapeutic efficiency and reduces undesirable side effects of the drugs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga, Punjab, India
References (42)
Show source-provided references
1. 10.1016/j.ijantimicag.2005.07.01210.1016/j.ijantimicag.2005.07.012 ↗
2. 10.1128/AAC.42.10.268210.1128/AAC.42.10.2682 ↗
3. 10.1016/j.ijpharm.2006.09.01710.1016/j.ijpharm.2006.09.017 ↗
4. 10.1016/j.addr.2003.10.01510.1016/j.addr.2003.10.015 ↗
5. 10.1016/j.ejps.2013.11.01610.1016/j.ejps.2013.11.016 ↗
6. 10.1093/jac/28.3.42510.1093/jac/28.3.425 ↗
7. 10.1128/AAC.01164-0610.1128/AAC.01164-06 ↗
8. 10.3109/21691401.2014.91671510.3109/21691401.2014.916715 ↗
9. 10.2174/2210304x1120204000510.2174/2210304x11202040005 ↗
10. 10.1517/17425247.2014.89101410.1517/17425247.2014.891014 ↗
11. 10.2174/2210303111303666001510.2174/22103031113036660015 ↗
12. 10.2174/2210304x1120204000310.2174/2210304x11202040003 ↗
13. 10.1615/CritRevTherDrugCarrierSyst.v29.i1.1010.1615/CritRevTherDrugCarrierSyst.v29.i1.10 ↗
14. 10.1615/CritRevTherDrugCarrierSyst.201300725910.1615/CritRevTherDrugCarrierSyst.2013007259 ↗
15. 10.1164/rccm.200504-613PP10.1164/rccm.200504-613PP ↗
16. 10.1007/978-3-662-45775-7_410.1007/978-3-662-45775-7_4 ↗
17. Goyal G · Drug Deliv · 2013
18. 10.1615/CritRevTherDrugCarrierSyst.201400811710.1615/CritRevTherDrugCarrierSyst.2014008117 ↗
19. 10.3109/10717544.2014.92876010.3109/10717544.2014.928760 ↗
20. 10.3109/10717544.2014.93553110.3109/10717544.2014.935531 ↗
21. 10.2174/2210303111303666001810.2174/22103031113036660018 ↗
22. 10.1615/CritRevTherDrugCarrierSyst.201400828510.1615/CritRevTherDrugCarrierSyst.2014008285 ↗
23. Kaur M · Drug Deliv · 2014
24. 10.3109/21691401.2014.98430210.3109/21691401.2014.984302 ↗
25. 10.3109/10717544.2014.99348610.3109/10717544.2014.993486 ↗
26. 10.1128/AAC.34.6.96710.1128/AAC.34.6.967 ↗
27. 10.2174/15672010777931479410.2174/156720107779314794 ↗
28. 10.1007/s11095-007-9302-810.1007/s11095-007-9302-8 ↗
29. 10.3109/10717544.2014.93553210.3109/10717544.2014.935532 ↗
30. 10.1093/jac/dki02710.1093/jac/dki027 ↗
31. 10.1016/j.tube.2004.11.00310.1016/j.tube.2004.11.003 ↗
32. 10.1093/jac/dkg47710.1093/jac/dkg477 ↗
33. 10.1016/j.tube.2005.08.00910.1016/j.tube.2005.08.009 ↗
34. Parnami N · Artif Cells Nanomed Biotechnol · 2013
35. 10.1093/jac/dkg16510.1093/jac/dkg165 ↗
36. Sharma A · Artif Cells Nanomed Biotechnol · 2014 · 1
37. 10.1093/jac/dkh41110.1093/jac/dkh411 ↗
38. 10.1615/CritRevTherDrugCarrierSyst.201400819310.1615/CritRevTherDrugCarrierSyst.2014008193 ↗
39. Singh B · Artif Cells Nanomed Biotechnol · 2014 · 1
40. Singh H · Artif Cells Nanomed Biotechnol · 2014
41. 10.1023/A:101309411286110.1023/A:1013094112861 ↗
42. 10.1016/j.ijpharm.2003.08.01710.1016/j.ijpharm.2003.08.017 ↗